Cytek
Builds Aurora spectral flow cytometers that profile 30-plus markers per sample on benchtop hardware.
Something off on this page? Send us feedback.
Profile
Makes spectral flow cytometers, led by the Aurora platform, that read each fluorochrome's full emission curve to profile 30 or more markers per sample. Instruments are sold alongside proprietary reagents, analysis software, and service contracts, with sales concentrated among pharmaceutical, biotech, and academic research customers.
Builds spectral flow cytometers that capture each fluorochrome's full emission curve instead of a single peak, letting labs run panels of 30 or more markers on benchtop hardware. The Aurora platform, introduced in 2017, anchors a lineup that now spans a lower-cost Northern Lights analyzer and a newer high-throughput Aurora Evo model.
A 2023 acquisition added imaging and conventional flow cytometry lines, broadening the hardware beyond the original spectral method. Instruments are sold alongside proprietary antibody reagents, unmixing and analysis software, and installation and maintenance services, so revenue continues through consumables and service contracts after each sale.
Most sales go to pharmaceutical, biotech, and contract-research customers, with the remainder in academic and government labs. Financial reporting treats the business as a single operating segment, split only between product and service revenue.
Company facts
Categories
Key statistics
Year to date −4.7% · Average volume (30d) 787.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | Morgan Stanley | Target | $5.50 | $5 | |
| May 13, 2026 | Stephens | Target | $4.75 | ||
| May 12, 2026 | Morgan Stanley | Reiterate | Equal Weight | $6 | $5.50 |
| Dec 1, 2025 | Morgan Stanley | Target | $6 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.09 | −$0.05 | +46.4% | $47.3M | $48.1M | +1.8% | −0.48% |
| May 7, 2026Q1 FY26 | −$0.08 | −$0.12 | −50.0% | $44.2M | $44.1M | −0.2% | −6.30% |
| Feb 26, 2026Q4 FY25 | −$0.02 | −$0.01 | +50.0% | $57.2M | $62.1M | +8.7% | +1.82% |
| Nov 5, 2025Q3 FY25 | $0.01 | −$0.01 | −200.0% | $58.8M | $52.3M | −11.1% | +13.22% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $41.5M | $45.6M | $52.3M | $62.1M | $44.1M | $48.1M | |
| Gross profit | $20.2M | $23.9M | $27.6M | $32.9M | $21.3M | $28.3M | |
| Operating income | −$15.0M | −$10.6M | −$9.2M | −$5.6M | −$18.5M | −$11.4M | |
| Net income | −$11.4M | −$5.6M | −$5.5M | −$44.1M | −$18.9M | −$12.2M | |
| Diluted EPS | −$0.09 | −$0.04 | −$0.04 | −$0.34 | −$0.15 | −$0.09 | |
| Gross margin | 48.6% | 52.3% | 52.7% | 52.9% | 48.2% | 58.9% | |
| Operating margin | -36.1% | -23.3% | -17.6% | -9.0% | -41.8% | -23.7% |
Fiscal years (4-quarter sums)FY21 $128.0M · FY22 $164.0M · FY23 $193.0M · FY24 $200.5M · FY25 $201.5M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $262.0M · Total debt $26.5M · Total assets $446.9M · Shareholders' equity $322.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 129.14M · Float 118.26M · 91.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.58M | 7.42% | 13F | Aug 7, 2026 |
| Millennium Management LLC | 9.34M | 7.23% | 13F | Aug 14, 2026 |
| Boston Partners | 7.64M | 5.91% | 13G | Aug 4, 2026 |
| Integrated Core Strategies (US) LLC | 6.97M | 5.40% | 13G | May 18, 2026 |
| HHLR Advisors, Ltd. | 6.66M | 5.15% | 13F | Aug 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- BD
Global #1 flow cytometry leader with deep clinical and research installed base
- Danaher
Beckman Coulter's CytoFLEX / DxFLEX / MoFlo hold the #2 global position
- Sony (ADR)
ID7000 spectral analyzer, Aurora's closest native full-spectrum rival
- Thermo Fisher Scientific
Attune acoustic-focusing cytometers and Invitrogen reagents overlap FSP
- Bio-Rad Laboratories
ZE5 flow cytometer and StarBright dye rival, plus a 2023 reagent-supply partner
- Agilent Technologies
NovoCyte benchtop analyzers undercut entry-level spectral flow tier
- Standard BioTools
CyTOF mass cytometry — adjacent 40+ parameter alternative to spectral flow
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cytek | $4.68 | −0.21% | $604.4M | — | — | 2.9 | +5.6% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Sony (ADR) | $24.71 | −0.56% | $145.93B | — | 28.9 | 1.8 | −1.6% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Standard BioTools | $0.6548 | +2.47% | $251.3M | — | — | 3.0 | −7.6% |
| Median | 38.4 | 24.1 | 4.0 | −0.1% |